title: Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management.
abstract: Even if the true incidence of hypoglycemia in type 2 diabetes mellitus (T2DM) remains difficult to estimate, with highly variable rates reported in the literature, it is likely more common than previously thought. While most hypoglycemic episodes in T2DM are considered "mild," they still have a substantial clinical impact. Severe hypoglycemia also exists in T2DM, with recent landmark studies prompting much debate about the potential role of severe hypoglycemia in cardiovascular morbidity and mortality, even though there is currently no definitive evidence for causality. The challenge in the treatment of T2DM remains the achievement of optimal glycemic control to lower the risk for long-term complications while avoiding hypoglycemia. Successful treatment strategies should therefore include careful selection of therapies to prevent hypoglycemia, starting early in the disease management process, in order to best preserve counterregulation. The dipeptidyl peptidase-4 inhibitor, vildagliptin, is a good treatment option to minimize the risk of hypoglycemia over time, while maintaining good glucose control. Extensive clinical experience is available for vildagliptin, with data published for all stages of the condition and with the low hypoglycemic potential stemming from a solid mechanistic basis.
authors: Novartis Pharma S.A.S, Clinical Research & Development, 2/4, Rue Lionel Terray, F-92500, Rueil-Malmaison, France, sylvie.dejager@novartis.com.
authors: Sylvie
authors: S
authors: Dejager
authors: Anja
authors: A
authors: Schweizer